Both CTLA-4 and PD-1 are up-regulated upon T cell activation and are hence predicted to constitute significant barriers to the success of therapeutics—including OVs—that endeavour to stimulate anti-tumour immunity [54]. Here, PDCD1 is linked to neoplasm.